Prevention of sickness absence through early identification and rehabilitation of at-risk patients with musculoskeletal disorders (PREVSAM): short term effects of a randomised controlled trial in primary care

To evaluate short-term effects of the PREVention of Sickness Absence for Musculoskeletal disorders (PREVSAM) model on sickness absence and patient-reported health outcomes. Patients with musculoskeletal disorders were randomised to rehabilitation according to PREVSAM or treatment as usual (TAU) in p...

Full description

Saved in:
Bibliographic Details
Published in:Disability and rehabilitation 2025-01, Vol.47 (1), p.164-14
Main Authors: Ekhammar, Annika, Grimby-Ekman, Anna, Bernhardsson, Susanne, Holmgren, Kristina, Bornhöft, Lena, Nordeman, Lena, Larsson, Maria E H
Format: Article
Language:English
Subjects:
Absenteeism
Adult
Female
Humans
interdisciplinary teamwork
Male
Middle Aged
Musculoskeletal Diseases - rehabilitation
Musculoskeletal pain
occupational therapy
Orthopedics
Ortopedi
Patient Reported Outcome Measures
physiotherapy
primary care
Primary Health Care
secondary prevention
Self Efficacy
Self Report
Sick Leave - statistics & numerical data
sickness absence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate short-term effects of the PREVention of Sickness Absence for Musculoskeletal disorders (PREVSAM) model on sickness absence and patient-reported health outcomes. Patients with musculoskeletal disorders were randomised to rehabilitation according to PREVSAM or treatment as usual (TAU) in primary care. Sickness absence and patient-reported health outcomes were evaluated after three months in 254 participants. The proportion of participants remaining in full- or part-time work were 86% in PREVSAM vs 78% in TAU (  = 0.097). The PREVSAM group had approximately four fewer sickness benefit days during three months from baseline ( range 0.078-0.126). No statistically significant difference was found in self-reported sickness absence days (PREVSAM 12.4 vs TAU 14.5;  = 0.634), nor were statistically significant differences between groups found in patient-reported health outcomes. Both groups showed significant improvements from baseline to three months, except for self-efficacy, and only the PREVSAM group showed significantly reduced depression symptoms. The findings suggest that for sickness absence, the PREVSAM model may have an advantage over TAU, although the difference did not reach statistical significance at the  
ISSN:0963-8288
1464-5165
1464-5165
DOI:10.1080/09638288.2024.2343424